Healthcare / Medical DevicesTaipei Exchange
$7.85
-0.17 (-2.08%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-32.3M · quality 66.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$814M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-20.1%
↓Gross Margin
31.8%
↓Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-12.7%
FCF CAGR
—
FCF margin
-62.6%
FCF / Net income
1.27x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $127.1M · net income $-62.5M · FCF $-79.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $127.1M | $127.1M | $128.1M | $167.2M | $191.2M |
| Net Income | $-62.5M | $-62.5M | $-61.6M | $-58.5M | $-53.1M |
| EBITDA | $-45.7M | $-45.7M | $-42.7M | $-40.3M | $-32.9M |
| EPS | — | — | -0.59 | -0.56 | -0.51 |
| Gross Margin | 31.8% | 31.8% | 38.5% | 37.4% | 30.9% |
| Operating Margin | -51.7% | -51.7% | -62.1% | -38.4% | -35.0% |
| Net Margin | -49.2% | -49.2% | -48.1% | -35.0% | -27.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.02 | 0.03 | 0.01 |
| Current Ratio | 3.58 | 3.58 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-79.5M | $-79.5M | $-8.6M | $-32.3M | $-73.5M |
| Returns | |||||
| ROE | -20.1% | -20.1% | -16.5% | -13.8% | -11.1% |
| Valuation | |||||
| P/B | 2.63 | 2.63 | 3.32 | 3.43 | 2.59 |
| Growth & Yield | |||||
| Revenue Growth | -0.8% | -0.8% | -23.4% | -12.6% | — |
| EPS Growth | — | — | -5.4% | -9.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-28.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.59 → n/d
Residual
-28.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.